Ingredient deep-dive

Eight Milligrams Of Pineapple Enzyme: What Bromelain Is Doing Here

Bromelain is the one row on this panel that cannot be compared with its own trials even in principle, and the reason is a unit rather than a number. Enzymes are sold by how much work they do, not by what they weigh, and this label prints a weight.

By FlexGuard Team · Last updated October 29, 2026 · 8 min read · Ingredient deep-dive · Reviewed by Dr. Edgar Martorell, MD

What bromelain is

Bromelain is not one substance. It is a mixture of proteolytic enzymes, which means enzymes that cut proteins apart, extracted from the pineapple plant along with a handful of other components.

The distinction that matters on a label is which part of the plant it came from. Stem bromelain and fruit bromelain are different materials with different enzyme profiles, and the commercial ingredient is almost always from the stem, which is a by-product of harvesting the fruit.

This panel says so: the row reads Bromelain (Ananas comosus)(stem). Naming the plant part in brackets is more than a good deal of this category bothers with, and it is the same courtesy the boswellia and turmeric rows get.

It is also, alongside the meat tenderiser on a supermarket shelf, one of the few supplement ingredients most people have already eaten deliberately.

Where its reputation comes from

Bromelain did not arrive in supplements through the joint aisle. It arrived through surgery.

In parts of Europe it has been used for decades for swelling and bruising after injury and after dental and orthopaedic procedures, and that is the setting most of its clinical record belongs to. The proposed mechanism is an effect on the proteins involved in swelling and clot breakdown rather than anything to do with cartilage.

That origin explains something about how it is sold. An ingredient with a post-surgical reputation reads as serious, and it carries that association onto a joint label whether or not the amount is comparable to the one that built the reputation.

The joint evidence, such as it is

A review of the bromelain studies in osteoarthritis collected the clinical work that exists. Its findings are worth stating carefully, because they are neither dismissive nor encouraging.

The trials are small. The designs vary, including comparisons against anti-inflammatory drugs and combinations with other enzymes rather than bromelain alone. The doses run in the hundreds of milligrams a day. The review's own conclusion is that the evidence is promising and insufficient, which is the correct reading of a literature that size.

None of that is a criticism of the ingredient. It is a description of how much is known, and how much is known is: not very much, at doses many times this one.

The left column is what the published studies used. It is not a prediction about this capsule, which has not been trialled at any amount.

Weight against activity: the problem with this row

Here is the part that makes bromelain different from every other row on this panel.

An enzyme is not defined by its weight. It is defined by how much work it can do, because a preparation can be more or less pure, more or less active, and partly degraded by heat or time. Two preparations weighing the same can differ several-fold in the only property anybody cares about.

So enzyme ingredients are normally sold and labelled in activity units, and for bromelain those are usually gelatin digesting units. A serious bromelain product prints an activity figure next to the weight, or instead of it.

This panel prints 8 mg and no activity figure. That is permitted: the labelling rule requires the amount of the ingredient, not a characterisation of its potency. What it means in practice is that this row cannot be compared with a trial that reported its dose in units, and it cannot be compared with another product's bromelain row either.

Two of the four, which is more than some labels give and less than the comparison in this article would need.

What this panel actually prints

Being precise about what is and is not there:

The plant and the part. Ananas comosus, stem. Both stated.

The weight. Eight milligrams per capsule, per serving, once a day.

No activity figure. No gelatin digesting units, no standardisation statement.

No enteric coating claim. Proteolytic enzymes taken by mouth meet stomach acid before anything else, and products that care about this say so on the label. This one does not mention it either way.

Eight milligrams is roughly one per cent of the capsule's 699 mg of declared actives. It is one of four rows at that weight, and together those four are under five per cent of the capsule. The ingredients page sets all eight rows out the same way.

Why an enzyme ends up on a joint label at all

• It has a genuine anti-swelling reputation from a different clinical setting, and reputations travel further than the settings that produced them.
• It is recognisable. Most people know pineapple contains something that stings the tongue, which makes the ingredient feel intuitive.
• It is cheap at this amount. Eight milligrams of anything is cheap.
• It is a name on a front label. Eight ingredients reads as more generous than two, and buyers count names.
• The same pattern repeats elsewhere on this panel. MSM's literature runs in grams and its row is 8 mg; quercetin's absorption is poor and its row is below what a plate of onions would supply.

None of those five is dishonest and none of them is a reason to expect anything from the row. They are a description of how a breadth formula gets assembled, and the panel is what lets a reader see the result.

The bleeding caution, in proportion

Bromelain carries a theoretical caution about bleeding, because a protein-digesting enzyme with an effect on clot breakdown is exactly the kind of thing that would interact with an anticoagulant.

That caution belongs to supplement doses, which is to say the hundreds of milligrams its trials used. At 8 mg this is a food-level amount, and a slice of fresh pineapple carries bromelain too.

The honest description is therefore theoretical rather than documented at this amount. The interaction on this panel that is worth raising with a prescriber is the glucosamine one, not this.

The exception is pineapple allergy, which is uncommon and real. Anybody who reacts to fresh pineapple should treat a bromelain row as a reason to check with whoever manages that, and NCCIH's short guide to using supplements sensibly makes the general version of that point.

Four things that would make this row checkable

1. An activity figure. Gelatin digesting units beside the milligrams, which is how the ingredient is normally traded.
2. A standardisation statement. That the preparation is made to a fixed activity per gram.
3. A note on the coating. Whether the capsule is intended to survive stomach acid, which matters more for an enzyme than for any other row here.
4. An amount in the region its own trials used. Which would mean a different product, because hundreds of milligrams of bromelain does not fit in a capsule already carrying 500 mg of glucosamine.

The fourth is the one that returns this article to where it started. Bromelain at a researched amount and glucosamine at a researched amount cannot both be in the same once-daily capsule, and this formula chose glucosamine. That is a defensible choice and it is the reason the bromelain row is what it is.

References